Study Evaluating SRA-333 in Mild to Moderate Alzheimer's Disease (AD)

Wyeth

Status and phase: Completed; Phase 2

Conditions: Alzheimer's Disease

Treatments: Drug: SRA-333

Study type: Interventional

Funder types: Industry

Identifiers

NCT00151333

3098A1-200

Details and patient eligibility

About

To determine the safety and tolerability of multiple ascending fixed oral doses of SRA-333 in subjects with mild to moderate Alzheimer's disease.

Sex: All

Ages: 50 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of probable AD according to the NINCDS-ADRDA criteria.
• Men and postmenopausal or surgically sterile women aged from 50 to 85 inclusive.
• Able to give informed consent. Patient's caregiver must consent to participate in the study.

Exclusion criteria

• Significant neurologic disease other than AD that may affect cognition.
• Current clinically significant systemic illness which is likely to deteriorate or affect the subject's safety during the study.

Other exclusions apply

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind